• norsk
    • English
  • norsk 
    • norsk
    • English
  • Logg inn
Vis innførsel 
  •   Hjem
  • University of Bergen Library
  • Registrations from Cristin
  • Vis innførsel
  •   Hjem
  • University of Bergen Library
  • Registrations from Cristin
  • Vis innførsel
JavaScript is disabled for your browser. Some features of this site may not work without it.

The association between lithium use and neurocognitive performance in patients with bipolar disorder

Burdick, Katherine E.; Millett, Caitlin E.; Russo, Manuela; Alda, Martin; Alliey-Rodriguez, Ney; Anand, Amit; Balaraman, Yokesh; Berrettini, Wade H.; Bertram, Holli; Calabrese, Joseph R.; Calkin, Cynthia V.; Conroy, Carla; Coryell, William; DeModena, Anna; Feeder, Scott; Fisher, Carrie; Frazier, Nicole; Frye, Mark; Gao, Keming; Garnham, Julie; Gershon, Elliot S.; Glazer, Kara; Goes, Fernando S.; Goto, Toyomi; Harrington, Gloria J.; Jakobsen, Petter; Kamali, Masoud; Kelly, Marisa; Leckband, Susan G.; Løberg, Else-Marie; Lohoff, Falk W.; Maihofer, Adam X.; McCarthy, Michael J.; McInnis, Melvin; Morken, Gunnar; Nievergelt, Caroline M.; Nurnberger, John I.; Oedegaard, Ketil J.; Ortiz, Abigail; Ritchey, Megan; Ryan, Kelly; Schinagle, Martha; Schwebel, Candice; Shaw, Martha; Shilling, Paul D.; Slaney, Claire; Stapp, Emma; Tarwater, Bruce; Zandi, Peter P.; Kelsoe, John R.
Journal article, Peer reviewed
Accepted version
Thumbnail
Åpne
Accepted version (412.0Kb)
Permanent lenke
https://hdl.handle.net/11250/2760690
Utgivelsesdato
2020
Metadata
Vis full innførsel
Samlinger
  • Department of Clinical Medicine [1484]
  • Registrations from Cristin [5233]
Originalversjon
Neuropsychopharmacology. 2020, 45, 1743–1749   10.1038/s41386-020-0683-2
Sammendrag
Lithium remains the gold standard for the treatment of bipolar disorder (BD); however, its use has declined over the years mainly due to the side effects and the subjective experience of cognitive numbness reported by patients. In the present study, we aim to methodically test the effects of lithium on neurocognitive functioning in the largest single cohort (n = 262) of BD patients reported to date by harnessing the power of a multi-site, ongoing clinical trial of lithium monotherapy. At the cross-sectional level, multivariate analysis of covariance (MANCOVA) was conducted to examine potential group differences across neurocognitive tests [California Verbal Learning Test (CVLT trials 1–5,CVLT delayed recall), Wechsler Digit Symbol, Trail-making Test parts A and B (TMT-A; TMT-B), and a global cognition index]. At the longitudinal level, on a subset of patients (n = 88) who achieved mood stabilization with lithium monotherapy, we explored the effect of lithium treatment across time on neurocognitive functioning. There were no differences at baseline between BD patients that were taking lithium compared with those that were not. At follow-up a significant neurocognitive improvement in the global cognitive index score [F = 31.69; p < 0.001], CVLT trials 1–5 [F = 29.81; p < 0.001], CVLT delayed recall [F = 15.27; p < 0.001], and TMT-B [F = 6.64, p = 0.012] was detected. The cross-sectional and longitudinal (on a subset of 88 patients) investigations suggest that lithium may be beneficial to neurocognitive functioning in patients with BD and that at the very least it does not seem to significantly impair cognition when used therapeutically.
Utgiver
Nature
Tidsskrift
Neuropsychopharmacology
Opphavsrett
Copyright 2020 The Authors

Kontakt oss | Gi tilbakemelding

Personvernerklæring
DSpace software copyright © 2002-2019  DuraSpace

Levert av  Unit
 

 

Bla i

Hele arkivetDelarkiv og samlingerUtgivelsesdatoForfattereTitlerEmneordDokumenttyperTidsskrifterDenne samlingenUtgivelsesdatoForfattereTitlerEmneordDokumenttyperTidsskrifter

Min side

Logg inn

Statistikk

Besøksstatistikk

Kontakt oss | Gi tilbakemelding

Personvernerklæring
DSpace software copyright © 2002-2019  DuraSpace

Levert av  Unit